AR122580A2 - Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales - Google Patents

Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales

Info

Publication number
AR122580A2
AR122580A2 ARP210101574A ARP210101574A AR122580A2 AR 122580 A2 AR122580 A2 AR 122580A2 AR P210101574 A ARP210101574 A AR P210101574A AR P210101574 A ARP210101574 A AR P210101574A AR 122580 A2 AR122580 A2 AR 122580A2
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
acceptable salt
doxylamine
pyridoxine
release
Prior art date
Application number
ARP210101574A
Other languages
English (en)
Inventor
Manon Vranderick
Jean St-Onge
- Gedeon Christelle Luc
Michele Gallo
Ric Gervais
Original Assignee
Duchesnay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49004884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR122580(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duchesnay Inc filed Critical Duchesnay Inc
Publication of AR122580A2 publication Critical patent/AR122580A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una forma de dosificación oral de liberación dual caracterizada porque comprende 5 mg a 40 mg de doxilamina y/o una sal farmacéuticamente aceptable de la misma y 5 mg a 50 mg de piridoxina y/o una sal farmacéuticamente aceptable de la misma, en donde dicha forma de dosificación oral de liberación dual comprende: (A) un núcleo que comprende una composición de liberación retardada que comprende: (a) doxilamina y/o una sal farmacéuticamente aceptable de la misma; y (b) piridoxina y/o una sal farmacéuticamente aceptable de la misma; y (B) un revestimiento de liberación retardada que comprende un agente de liberación retardada que rodea dicho núcleo; y, (C) uno o varios recubrimientos que rodean dicho revestimiento de liberación retardada y que comprenden una composición de liberación inmediata que comprende: (a) doxilamina y/o una sal farmacéuticamente aceptable de la misma; y (b) piridoxina y/o una sal farmacéuticamente aceptable de la misma; en donde dicha composición de liberación inmediata es para efectuar la liberación de (a) doxilamina y/o una sal farmacéuticamente aceptable de la misma, y (b) piridoxina y/o una sal farmacéuticamente aceptable de la misma, dentro del estómago, y dicha composición de liberación retardada es para efectuar la liberación de (a) doxilamina y/o una sal farmacéuticamente aceptable de la misma, y (b) piridoxina y/o una sal farmacéuticamente aceptable de la misma, dentro del intestino, y no hay liberación desde la composición de liberación retardada en el estómago.
ARP210101574A 2012-02-22 2021-06-09 Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales AR122580A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261601754P 2012-02-22 2012-02-22

Publications (1)

Publication Number Publication Date
AR122580A2 true AR122580A2 (es) 2022-09-21

Family

ID=49004884

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130100543A AR090126A1 (es) 2012-02-22 2013-02-22 Composicion de doxilamina y piridoxina y/o sus metabolitos o sales
ARP210101574A AR122580A2 (es) 2012-02-22 2021-06-09 Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP130100543A AR090126A1 (es) 2012-02-22 2013-02-22 Composicion de doxilamina y piridoxina y/o sus metabolitos o sales

Country Status (25)

Country Link
US (3) US9089489B2 (es)
EP (2) EP2787971A4 (es)
JP (2) JP5914701B2 (es)
KR (1) KR101588259B1 (es)
CN (1) CN104136004B (es)
AR (2) AR090126A1 (es)
AU (1) AU2013224598B2 (es)
BR (1) BR112014020186A8 (es)
CA (1) CA2848798C (es)
CL (1) CL2014001828A1 (es)
CY (1) CY1123122T1 (es)
DK (1) DK3326611T3 (es)
ES (1) ES2809713T3 (es)
HK (1) HK1197035A1 (es)
HU (1) HUE052301T2 (es)
IL (1) IL233644A (es)
LT (1) LT3326611T (es)
MX (1) MX355912B (es)
NZ (1) NZ627593A (es)
PL (1) PL3326611T3 (es)
PT (1) PT3326611T (es)
SG (1) SG11201403931YA (es)
TW (1) TWI638657B (es)
UY (1) UY34631A (es)
WO (1) WO2013123595A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2787971A4 (en) 2012-02-22 2015-04-29 Duchesnay Inc FORMULATION OF DOXYLAMINE AND PYRIDOXINE AND / OR THEIR METABOLITES OR SALTS
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
MX366760B (es) 2013-07-22 2019-07-23 Duchesnay Inc Composición para la gestión de las náuseas y los vómitos.
CN103432126A (zh) * 2013-08-05 2013-12-11 北京阜康仁生物制药科技有限公司 一种治疗孕吐的药物组合物
WO2016029290A1 (en) * 2014-08-29 2016-03-03 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
CA2995431A1 (en) 2015-08-17 2017-02-23 Aequus Pharmaceuticals Inc. Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride
EP3697392B1 (en) 2017-10-17 2023-11-15 Synthon B.V. Tablets comprising tamsulosin and solifenacin
RS61368B1 (sr) * 2018-09-27 2021-02-26 Inibsa Ginecologia S A Postupak za pripremu višejediničnog oralnog doznog oblika sa modifikovanim oslobađanjem doksilamin sukcinata i piridoksin hidrohlorida
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
WO2022254277A1 (en) * 2021-05-31 2022-12-08 Maneesh Pharmaceuticals Ltd Extended release composition and its process for the preparation
AU2021225255B1 (en) * 2021-09-03 2022-06-16 Patel, Mihir MR Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting.

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ286242A (en) 1991-03-26 1997-11-24 Csl Ltd Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US7744916B2 (en) 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
EP1191924A4 (en) 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL PHARMACEUTICAL FORM FOR PULSED ADMINISTRATION OF (D-THREO) METHYLPHENIDATE AND ANOTHER CNS STIMULATING SUBSTANCE
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2350195C (en) 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
JP4657577B2 (ja) 2001-01-09 2011-03-23 マイクロチップス・インコーポレーテッド 眼への適用および他への適用のための可撓性マイクロチップデバイス
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7704542B2 (en) 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
WO2004071487A2 (en) 2002-08-16 2004-08-26 Microchips, Inc. Controlled release device and method
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
DE602005013253D1 (de) 2004-09-01 2009-04-23 Microchips Inc Behältervorrichtungen mit mehreren verschlüssen zur gesteuerten abgabe oder exponierung des behälterinhalts
GB0502475D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
JP5514547B2 (ja) 2007-09-14 2014-06-04 ロート製薬株式会社 眼科用組成物
KR101190708B1 (ko) * 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
US9884022B2 (en) * 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
KR20140007247A (ko) * 2010-06-22 2014-01-17 티더블유아이 파머수티컬스, 인코포레이티드 음식물 영향이 감소된 제어 방출 조성물
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
EP2787971A4 (en) 2012-02-22 2015-04-29 Duchesnay Inc FORMULATION OF DOXYLAMINE AND PYRIDOXINE AND / OR THEIR METABOLITES OR SALTS
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting

Also Published As

Publication number Publication date
CA2848798C (en) 2014-12-23
AU2013224598A1 (en) 2014-07-31
DK3326611T3 (da) 2020-08-17
JP2016053092A (ja) 2016-04-14
US20160374946A1 (en) 2016-12-29
KR101588259B1 (ko) 2016-01-25
PT3326611T (pt) 2020-08-20
US9089489B2 (en) 2015-07-28
IL233644A0 (en) 2014-08-31
CN104136004B (zh) 2018-03-06
AR090126A1 (es) 2014-10-22
LT3326611T (lt) 2020-08-25
TW201334780A (zh) 2013-09-01
ES2809713T3 (es) 2021-03-05
BR112014020186A8 (pt) 2017-07-11
US9937132B2 (en) 2018-04-10
CA2848798A1 (en) 2013-08-29
MX355912B (es) 2018-05-04
IL233644A (en) 2016-05-31
CL2014001828A1 (es) 2014-11-14
NZ627593A (en) 2015-12-24
CN104136004A (zh) 2014-11-05
EP3326611B1 (en) 2020-05-06
US20140314680A1 (en) 2014-10-23
EP2787971A4 (en) 2015-04-29
HK1197035A1 (en) 2015-01-02
SG11201403931YA (en) 2014-08-28
JP5914701B2 (ja) 2016-05-11
UY34631A (es) 2013-09-30
TWI638657B (zh) 2018-10-21
EP2787971A1 (en) 2014-10-15
PL3326611T3 (pl) 2020-11-02
HUE052301T2 (hu) 2021-04-28
AU2013224598B2 (en) 2015-09-17
JP2015508082A (ja) 2015-03-16
EP3326611A1 (en) 2018-05-30
CY1123122T1 (el) 2021-10-29
MX2014008594A (es) 2015-03-03
BR112014020186A2 (es) 2017-06-20
WO2013123595A1 (en) 2013-08-29
US9375404B2 (en) 2016-06-28
US20150366808A1 (en) 2015-12-24
KR20140139496A (ko) 2014-12-05

Similar Documents

Publication Publication Date Title
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
GT201600142A (es) Composiciones farmacéuticas que comprenden azd9291
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
PE20161373A1 (es) Composiciones de liberacion retardada de linaclotida
CO7310528A2 (es) Composición farmacéutica recubierta que contiene regorafenib
ES2509117T3 (es) Composición farmacéutica oral que contiene dabigatran etexilato
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
JP2015038135A5 (es)
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
AR097644A1 (es) Composiciones farmacéuticas que contienen refametinib, uso y método de tratamiento
PH12016500693A1 (en) Slow-release solid oral compositions
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
JP2016513680A5 (es)
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
TR201722039A2 (tr) Mesalazi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
AR083322A1 (es) Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo
CL2015002251A1 (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
ES2468665B1 (es) Composición farmacéutica de sulfato de condroitina y celecoxib
EA201200799A1 (ru) Гепатопротекторное средство